Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of lung cancer. Malignant tumors can proliferate indefinitely, and cell cycle regulation is abnormal which is one of the characteristics of malignant tumor. Cyclin D-dependent kinase (CDK) 4/6 inhibitor can prevent tumor cells from entering S phase through G₁ phase and inhibit tumor proliferation. The CDK4/6 inhibitor has achieved good effect in hormone receptor positive breast cancer, and CDK4/6 inhibitor combined with endocrine therapy has become a standard treatment for this kind of patients. Cell cycle regulation is usually abnormal in NSCLC, which incidence is about 22%-45%. CDK4/6 inhibitors have also carried out a series of research and achieved some results, which may become a new treatment in the future. This review focuses on the research progress of CDK4/6 inhibitors in NSCLC, including the mechanism and the approved drugs, clinical research progress in NSCLC, biomarkers for efficacy prediction and current limitations.
【中文题目：CDK4/6抑制剂在非小细胞肺癌治疗中的研究进展】 【中文摘要：肺癌是全球癌症相关死亡的首要原因，非小细胞肺癌（non-small cell lung cancer, NSCLC）占肺癌的80%-85%。恶性肿瘤可以无限增殖，细胞周期失调控是恶性肿瘤特征之一。细胞周期依赖激酶（cyclin D-dependent kinase, CDK）4/6抑制剂能阻滞肿瘤细胞通过G₁期进入S期从而抑制肿瘤增殖，该药物在激素受体阳性乳腺癌中取得了良好的疗效，联合内分泌治疗成为这类患者一线标准治疗。细胞周期失控在NSCLC中比较常见，发生率约为22%-45%，CDK4/6抑制剂也进行了一系列的探索研究，并取得一定的效果，将来有可能成为新的治疗手段。本文重点讨论CDK4/6抑制剂在NSCLC的研究进展，包括作用机制、获批药物、在NSCLC中的临床研究进展、疗效预测生物标记物及局限性等。】 【中文关键词：肺肿瘤；细胞周期蛋白D；CDK4/6抑制剂；生物标记物】.
Keywords: Biomarkers; CDK4/6 inhibitors; Cyclin D; Lung neoplasms.